Gilead Extends Tender Offer for Arcellx Shares to 2030
Gilead Sciences (GILD) extended the expiration of the tender offer to purchase all outstanding shares of common stock of Arcellx (ACLX). The offer remains at a purchase price of (1) $115.00 per share, net to the seller in cash, without interest, subject to any withholding tax, plus (2) one contractual contingent value right , which represents the right to receive one contingent payment of $5.00 per CVR in cash, without interest, and subject to any withholding tax, payable on March 31, 2030, subject to cumulative worldwide sales of Arcellx's anitocabtagene autoleucel (anito-cel) product exceeding $6.0 billion on or prior to December 31, 2029.
